The Center for Biosimilars

Eye on Pharma: Celltrion's Tocilizumab biosimilar shows promise in Phase 3 data! This could mean increased access to this treatment for rheumatoid arthritis patients. Plus, in other biosimilar news: Formycon starts clinical development of their Pembrolizumab biosimilar. Stay ahead of the curve with the latest updates on biosimilars! https://lnkd.in/eSZMjdNu

Top 3 Game-Changing Biosimilars You NEED to Know About! Wondering what's next in the biosimilar world? We sat down with Jeffrey Casberg, SVP of Pharmacy at IDP Analytics, who reveals the top 3 promising specialty drugs coming down the pipeline!** They're tackling HUGE areas like Alzheimer's, Fatty Liver Disease, and Pulmonary Hypertension!** 🫀 🫁 But there's a twist! The FDA is taking a closer look at one of them. What could it mean? Click the link to watch and hear all about: https://lnkd.in/e5Bi2n_j

Confused about rising drug costs? Watch a segment of our interview with Jeffrey Casberg, SVP of Pharmacy at IDP Analytics, to get the inside scoop on what's driving these high prices! Want to know what the future holds for drug affordability? Click the link to watch the interview 🎥 https://lnkd.in/euBQWQud

Want to stay up-to-date on the latest biosimilar approvals and research? Check out this week's top 5 articles! This week's biosimilar news is all about treatment access, provider confidence, and interchangeability. https://lnkd.in/enQGbQWQ

Biosimilars Battle Cancer: New Wins You Need to Know! Docs just dropped the mic on biosimilars in oncology! ️We're talking new research, doc success stories, and how these treatments are changing the game for patients. ⚕️ Want to know more? We've got the scoop in this month's Biosimilars Oncology Roundup! https://lnkd.in/ePPx3MDr

Freedom Rings for Patients With nAMD! 🎆This Independence Day we're celebrating more than just fireworks! Formycon's Ahzantive (aflibercept-mrbb) just became the third biosimilar approved by the FDA to treat eye conditions! What's the big deal? Well, head over to the link to learn how Ahzantive stacks up against the competition. https://lnkd.in/eaUfP7SQ

Are you psyched about the FDA approval of Samsung Bioepis' Pyzchiva (uskekinumab-ttwe)? This drug treats patients with inflammatory conditions like plaque psoriasis and ulcerative colitis as the 3rd biosimilar referencing Stelara (ustekinumab) to hit the US market, AND it's interchangeable! For the full scoop: https://lnkd.in/etyC7rq6

The FDA just changed the game by shaking things up with interchangeable biosimilars. BUT, there's a twist! Want to know how this impacts developers, patients, and maybe even ethics? Head over to the link and join Sarfaraz K. Niazi as he unravels the drama! https://lnkd.in/eF8W8M6D

New study shows promise with an at-home treatment for patients with Crohn disease or Ulcerative Colitis! Infliximab biosimilar, CT-P13, was more effective than placebo in maintaining remission for patients with Crohn disease and Ulcerative Colitis. This is exciting news because it offers a potentially more convenient and effective treatment option for people battling these chronic conditions. For more information: Check out the full study here: https://lnkd.in/eCtXXxXQ

Feeling good & fighting strong with biosimilars? New research from #EHA2024 suggests biosimilar versions of a key lymphoma treatment might improve quality of life and reduce side effects! Want to know more? Check this out: https://lnkd.in/eWkRn77C